Yohei Masugi
YOU?
Author Swipe
View article: Intraepithelial Lymphocytes and LAIR1 Expression in Celiac Disease
Intraepithelial Lymphocytes and LAIR1 Expression in Celiac Disease Open
Background: Celiac disease (CD) is a gluten-sensitive immune-related enteropathy of the small intestine characterized by villus atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes (IELs). Objectives: To characterize the p…
View article: Supplementary Table S2 from Associations between Calcium Intake and T-cell Infiltration in Colorectal Tumors
Supplementary Table S2 from Associations between Calcium Intake and T-cell Infiltration in Colorectal Tumors Open
Supplementary Table S2: Associations between total calcium intake and tumour infiltrating lymphocytes stratified by CASR expression in the tumour
View article: Supplementary Table S3 from Associations between Calcium Intake and T-cell Infiltration in Colorectal Tumors
Supplementary Table S3 from Associations between Calcium Intake and T-cell Infiltration in Colorectal Tumors Open
Supplementary Table S3: Associations between calcium intake and tumour infiltrating lymphocytes using inverse transformed linear regression models
View article: Supplementary Table S1 from Associations between Calcium Intake and T-cell Infiltration in Colorectal Tumors
Supplementary Table S1 from Associations between Calcium Intake and T-cell Infiltration in Colorectal Tumors Open
Supplementary Table S1: Distribution and categorization of T-cell data.
View article: Data from Associations between Calcium Intake and T-cell Infiltration in Colorectal Tumors
Data from Associations between Calcium Intake and T-cell Infiltration in Colorectal Tumors Open
Higher T-cell infiltration in colorectal tumors has been associated with better prognosis. Evidence indicates that calcium signaling is essential for T-cell functioning. However, as it is unknown whether calcium intake influences T-cell in…
View article: Mirror syndrome and placental ectopic liver in association with de novo SOS1 variant
Mirror syndrome and placental ectopic liver in association with de novo SOS1 variant Open
Mirror syndrome is a rare obstetric condition characterized by maternal fluid retention mirroring fetal hydrops. Placental ectopic liver tissue is an extremely rare non-trophoblastic placental tumor, potentially arising from aberrant hepat…
View article: Supplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
QIAGEN Ingenuity Pathway Analysis results for unfolded protein response, filtered by DESeq2 analysis of AGR2 KO vs. control with abs(logFC) of >1.5 (p < 0.0005) (QIAGEN Inc., https://digitalinsights.qiagen.com/IPA). In the molecule, pink i…
View article: Supplementary Figure S1. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Figure S1. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Dose–response curve of carboplatin in six clear cell ovarian cancer organoids CCC, clear cell ovarian cancer
View article: Supplementary Table S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Table S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Cdk1/2/5/9 gene expression differences between dinaciclib-resistant CCC organoids (19-055, 19-076, and 19-079) vs. the dinaciclib-sensitive CCC organoids (180-015, 19-001, 19-010, 19-042, 19-044, 18-148). A log fold change (logFC) greater …
View article: Supplementary Figure S5. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Figure S5. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Immunoblot analysis of AGR2-knockout 18-015 organoid showing no upregulation of SLFN11
View article: Histological Image Classification Between Follicular Lymphoma and Reactive Lymphoid Tissue Using Deep Learning and Explainable Artificial Intelligence (XAI)
Histological Image Classification Between Follicular Lymphoma and Reactive Lymphoid Tissue Using Deep Learning and Explainable Artificial Intelligence (XAI) Open
Background/Objectives: The major question that confronts a pathologist when evaluating a lymph node biopsy is whether the process is benign or malignant, and the differential diagnosis between follicular lymphoma and reactive lymphoid tiss…
View article: Supplementary Table S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Table S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Cdk1/2/5/9 gene expression differences between dinaciclib-resistant CCC organoids (19-055, 19-076, and 19-079) vs. the dinaciclib-sensitive CCC organoids (180-015, 19-001, 19-010, 19-042, 19-044, 18-148). A log fold change (logFC) greater …
View article: Supplementary Figure S5. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Figure S5. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Immunoblot analysis of AGR2-knockout 18-015 organoid showing no upregulation of SLFN11
View article: Figure 1 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figure 1 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Establishment of a CCC organoid biobank. A, Clinicopathologic characteristics of the 11 cases of CCC from which organoids were derived. NED, no evidence of disease; OS, overall survival; PFS, progression-free survival. B, ssG…
View article: Supplementary Figure S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Figure S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
AGR2-knockout (KO) in AGR2-low clear cell ovarian cancer (CCC) did not suppress cell growth A, Immunoblot analysis confirmed AGR2 KO. B, AGR2 KO did not suppress cell growth in AGR2-low CCC organoid (18-015).
View article: Figure 3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figure 3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
An HTDS with 4,560 compounds identified PIs and dinaciclib as candidate drugs for CCC, demonstrating effectiveness in vivo. A, Schematic presentation of HTDS with 4,560 compounds for two CCC organoids (18-015 and 19-042). DHF…
View article: Figure 5 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figure 5 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
AGR2-high CCC organoids are sensitive to bortezomib, and AGR2 knockout reduces tumor growth. A, Heatmap showing the IC50 of drugs selected through the HTDS of 361 compounds (Fig. 2) of nine organoids (18-015, 19-07…
View article: Supplementary Figure S1. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Figure S1. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Dose–response curve of carboplatin in six clear cell ovarian cancer organoids CCC, clear cell ovarian cancer
View article: Figure 6 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figure 6 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
AGR2 knockout sensitizes CCC organoids to carboplatin through upregulation of SLFN11 and induces UPR and ER stress. A, Dose–response curve of bortezomib, dinaciclib, and carboplatin in AGR2-KO organoids. AGR2-KO…
View article: Supplementary Figure S4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Figure S4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Box plot showing Single-sample Gene Set Enrichment Analysis (ssGSEA) scores significantly different between AGR2-knockout organoids and controls (HALLMARK_WNT_BETA_CATENIN_SIGNALING, HALLMARK_P53_PATHWAY, HALLMARK_PEROXISOME, HALLMARK_EPIT…
View article: Data from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Data from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
There are currently no effective treatments available for clear cell ovarian cancer (CCC). In this study, we aimed to identify effective drugs for CCC through high-throughput drug screening (HTDS) using ovarian cancer organoids and determi…
View article: Supplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
QIAGEN Ingenuity Pathway Analysis results for unfolded protein response, filtered by DESeq2 analysis of AGR2 KO vs. control with abs(logFC) of >1.5 (p < 0.0005) (QIAGEN Inc., https://digitalinsights.qiagen.com/IPA). In the molecule, pink i…
View article: Figure 4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figure 4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
The activation of the UPR in CCC, with a higher level of activation observed following treatment with bortezomib. A, GSEA of the IRE1α pathway, PERK pathway, and ATF6 pathway in CCC, multiple myeloma from TCGA, and normal ovary from…
View article: Supplementary Table S1 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Table S1 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Compounds with inhibition efficiency over 70% (n = 103) in two clear cell ovarian cancer organoids (18-015, 19-042).
View article: Supplementary Table S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Supplementary Table S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
Gene expression differences between AGR2-knockout clear cell ovarian cancer organoids and controls (19-042)
View article: Figure 2 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Figure 2 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
HTDS for CCC organoids using a 384-well plate. A, ATP luminescence-based HTDS system. B, Two independent HTDS showed reproducible results in two CCC organoids. C, Schematic presentation of HTDS with 361 compounds for s…
View article: Smoking habit and long-term colorectal cancer incidence by exome-wide mutational and neoantigen loads: evidence based on the prospective cohort incident-tumour biobank method
Smoking habit and long-term colorectal cancer incidence by exome-wide mutational and neoantigen loads: evidence based on the prospective cohort incident-tumour biobank method Open
Objective To test the hypothesis that the association of smoking with long-term colorectal cancer incidence may be stronger for tumours with higher mutational and neoantigen loads. Methods and analysis In the Nurses’ Health Study (1980–201…
View article: High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target Open
There are currently no effective treatments available for clear cell ovarian cancer (CCC). In this study, we aimed to identify effective drugs for CCC through high-throughput drug screening (HTDS) using ovarian cancer organoids and determi…
View article: Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer
Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer Open
The cytology of SFM in PC is associated with a prognosis comparable to that of MAL, suggesting the need for cautious clinical interpretation and potential reclassification.
View article: Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification
Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification Open